加权
赛马鲁肽
灵敏度(控制系统)
蒙特卡罗方法
机器学习
临床试验
计算机科学
亲脂性
医学
人工智能
兴奋剂
数学
药理学
多准则决策分析
结果(博弈论)
风险分析(工程)
化学
选择(遗传算法)
口服
临床实习
数学优化
心理学
计量经济学
运筹学
药代动力学
参数统计
推论
生物等效性
概率逻辑
计算生物学
数据挖掘
作者
Lorika Sahu,Laxmipriya Nayak,Aakankshya Tripathy,Sivaramakrishnan Ramachandiran,Baranika Gunasekaran,Tejasri Lokaiah
标识
DOI:10.1177/15578100261499499
摘要
Incretin-based agents are transforming obesity pharmacotherapy, and orforglipron, the first oral non-peptide GLP-1 receptor agonist to complete phase 3 testing, invites direct comparison with the injectable agents semaglutide and tirzepatide. We integrated clinical trial evidence, including the direct head-to-head SURMOUNT-5 trial, independently verified molecular descriptors, a fully specified drug-target-disease network with permutation-tested hub significance, hypergeometric pathway enrichment, and multi-criteria decision analysis (MCDA) across four weighting schemes with formal sensitivity analysis. Tirzepatide produced significantly greater weight loss than semaglutide under randomized, head-to-head conditions (20.2% vs. 13.7% at week 72) and ranked highest under balanced, efficacy-, and safety-dominant MCDA models once a composite ADMET score misapplied to two large peptides was removed. Orforglipron's lipophilicity exceeds the Lipinski ceiling, showing that its oral absorption reflects deliberate chemistry rather than default small-molecule developability; it nonetheless ranked highest under an accessibility-dominant model driven by oral feasibility and manufacturing scalability. These rankings were stable under Monte Carlo sensitivity analysis for three of four weighting schemes, with the balanced model comparatively fragile. Tirzepatide's cardiovascular evidence has also advanced, with SURPASS-CVOT reporting non-inferiority to dulaglutide. No single agent dominates every criterion; treatment selection should match the clinical priority the individual patient weights most heavily.
科研通智能强力驱动
Strongly Powered by AbleSci AI